Maze Therapeutics, Inc. (MAZE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | CEO & Director | 812.26k | -- | 1976 |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research & Development and Chief Medical Officer | 764.17k | -- | 1960 |
| Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary | 354.78k | -- | 1976 |
| Ms. Amy Bachrodt | Senior VP of Finance & CFO | -- | -- | -- |
| Mr. Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations | -- | -- | -- |
| Mr. Matt Krause | Senior Vice President of Human Resources | -- | -- | -- |
| Mr. Atul Dandekar | Chief Strategy & Business Officer | -- | -- | 1972 |
| Ms. Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain | -- | -- | 1964 |
| Mr. Maarten Hoek | Senior Vice President of Research | -- | -- | -- |
| Mr. Winston Tse | Senior Vice President of Drug Discovery | -- | -- | -- |
Maze Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 125
Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Corporate Governance
Upcoming Events
May 14, 2025 at 8:01 PM UTC
Maze Therapeutics, Inc. Earnings Date